First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals. - Wikidata - awgldk - TriplyDB

First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals.

First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals.

http://www.wikidata.org/entity/Q30421150

about

Signal for Thrombosis with Eltrombopag and Romiplostim: A Disproportionality Analysis of Spontaneous Reports Within VigiBase®.The Quality of Clinical Information in Adverse Drug Reaction Reports by Patients and Healthcare Professionals: A Retrospective Comparative Analysis.Consumer reporting of adverse events following immunization (AEFI): identifying predictors of reporting an AEFI.Adverse drug reactions reported by consumers for nervous system medications in Europe 2007 to 2011 The value of patient reporting to the pharmacovigilance system: a systematic review.ADR Reporting by the General Public: Lessons Learnt from the Dutch and Swedish Systems.Informativeness of patient initial reports of adverse drug reactions. Can it be improved by a pharmacovigilance centre?Knowledge and attitude of health-care professionals in hospitals towards pharmacovigilance in Saudi Arabia.Comment on "Patient Reporting in the EU: Analysis of EudraVigilance Data".Pharmacovigilance: empowering healthcare professionals and patients.Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trial.Does patient reporting lead to earlier detection of drug safety signals? A retrospective comparison of time to reporting between patients and healthcare professionals in a global database

P2860

Q33425628-30C8FDAC-BFF8-47BB-BE0F-5F69C3706404 Q33845548-70D5E56D-34E6-43E4-9066-C65B0D6FBE48 Q34033938-AAF64910-B399-4D0C-BE4F-10712447A14F Q34771486-3287F733-BA3D-4864-9C5F-13A7D086DA69 Q36112324-5BE412B1-26FB-42FD-BC94-3FFCA5EEE01D Q38334927-390FBB61-FAD7-4644-B4EF-8AE5C4851B17 Q39229385-C9168AD4-5701-4F1F-9305-1ABBF64DF8CA Q40690033-7793D151-A829-410E-B4CC-FEA597D7CF07 Q46378567-CE882CFE-E810-4D3A-B924-A479B3A5CFF2 Q47732295-65D1A853-BF23-48D3-9F48-1455B069F469 Q52664035-E9B2B315-7ECE-437C-A7EE-A8E9AB02791B Q52664572-A029E656-0931-445A-A7C2-8B6A6C51BDBF

P2860

First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals.

http://www.wikidata.org/entity/Q30421150

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

First French experience of ADR ...... and healthcare professionals.

@ast

First French experience of ADR ...... and healthcare professionals.

@en

type

label

First French experience of ADR ...... and healthcare professionals.

@ast

First French experience of ADR ...... and healthcare professionals.

@en

prefLabel

First French experience of ADR ...... and healthcare professionals.

@ast

First French experience of ADR ...... and healthcare professionals.

@en

P1433

Q30421150-02E26228-DFCB-47A3-A42E-3CBBCC79F0AA

P1476

Q30421150-D586B2A7-8110-42BB-8945-AD311DB6C986

P2093

Q30421150-060BABA4-3BFD-4CC6-AECF-8ADE9064B262

Q30421150-09737039-2DB6-4DC9-AA7E-9C1F8CCD1EAA

Q30421150-2036E7EA-FFCB-47F0-8ED0-1A165ED936E5

Q30421150-3D1F536D-5871-4A41-B2CA-C8EB64035990

Q30421150-53A2FB06-06C3-441E-937D-A3773A02AEA5

Q30421150-8D190ACB-D38A-4005-A646-D28598D5F4E5

Q30421150-E0634EC4-7161-4F81-BCA4-84EAD413EECD

Q30421150-E5C19FAC-2E4C-4BBD-91F5-5AB7018715C6

Q30421150-FCDF4206-CA89-4CF7-9E40-A694EDDBCBC7

P2860

Q30421150-15BF58C7-F6E8-4740-8DC7-64916D209356

Q30421150-19440252-189A-4397-B134-46CB4E668519

Q30421150-50CF4422-30A4-4241-A020-2FC5B8FB1C39

Q30421150-5F779F70-ED5D-4FEC-8B13-056E25BCCC4E

Q30421150-6A08BC30-37EB-4CC5-81A9-E40DD0030156

Q30421150-6C866074-787B-4FE8-BD09-6FE0AE9AF8C3

Q30421150-7347C856-EF53-4103-BE40-27A214D65FAC

Q30421150-A2AED248-5709-4EC3-9119-D0BC1B526080

Q30421150-A4E6AF42-16CF-449C-8E4D-7281DD7FBEF1

Q30421150-AC1AB49E-0BD4-4C81-81D4-1A2D2A9D24F4

P2888

Q30421150-2B973E7E-D90F-4B8D-A6CF-1E1084639B60

P304

Q30421150-2A5045D0-86BE-4D81-8388-48BC711635C9

P31

Q30421150-85986178-AF0B-4C40-8AC4-111D7143F5BF

P356

Q30421150-03E7015F-D685-41DE-866C-FAA7BFFF38E8

P433

Q30421150-FD354CCF-19BE-40BE-82E4-ED5CF41AACB3

P478

Q30421150-7B3E309B-D3B0-42A0-914C-211221C6B8DF

P50

Q30421150-208C5044-2FC8-465E-8BAD-63464FDF3CEE

Q30421150-3D497A64-1B3A-426E-93F6-338EE92684E4

Q30421150-80A143DE-BAFB-4A50-8A0E-B4A7D573C664

Q30421150-DDC71CFD-800D-4C0B-9CD2-C128D704307D

P577

Q30421150-B502F4C4-BA47-4CA5-9C93-65DF3F42577A

P5875

Q30421150-E78A8675-C1CB-4025-9FF6-0F9C8D85BD19

P6179

Q30421150-44DCA124-CD2A-4988-B506-0666E8D92294

P698

Q30421150-10C1D1D9-4A50-4DF9-8C0F-B4DE6F925FA3

P921

Q30421150-81C83D60-2D8C-4667-97C5-CC27036C8AC2

P356

P1433

P1476

First French experience of ADR ...... and healthcare professionals.

@en

P2093

Alexis Jacquet

http://www.w3.org/2001/XMLSchema#string

Angeline Faucher

http://www.w3.org/2001/XMLSchema#string

Anne Castot

http://www.w3.org/2001/XMLSchema#string

Carmen Kreft-Jais

http://www.w3.org/2001/XMLSchema#string

French Network of Pharmacovigilance Centres

http://www.w3.org/2001/XMLSchema#string

Geneviève Durrieu

http://www.w3.org/2001/XMLSchema#string

Laure Pourcel

http://www.w3.org/2001/XMLSchema#string

Marie Christine Perault-Pochat

http://www.w3.org/2001/XMLSchema#string

Shéhérazade Ouaret

http://www.w3.org/2001/XMLSchema#string

P2860

Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring.

Population and risk group uptake of H1N1 influenza vaccine in mainland France 2009-2010: results of a national vaccination campaign.

Monitoring adverse events of the vaccination campaign against influenza A (H1N1) in the Netherlands.

Consumer adverse drug reaction reporting: a new step in pharmacovigilance?

Patients as a direct source of information on adverse drug reactions.

Patient reporting of suspected adverse drug reactions: a review of published literature and international experience.

Comparing patients' and healthcare professionals' ADR reports after media attention: the broadcast of a Dutch television programme about the benefits and risks of statins as an example

Adverse drug reactions: definitions, diagnosis, and management.

Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals.

Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006.

P2888

P304

845-854

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/BF03261980

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Louis Montastruc

Maryse Lapeyre-Mestre

Céline Caillet

P577

2012-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257286942

http://www.w3.org/2001/XMLSchema#string

P6179

1011659675

http://www.w3.org/2001/XMLSchema#string

P698

22967189

http://www.w3.org/2001/XMLSchema#string

P921